Search Results - "рекомбинантный эритропоэтин"

1

Academic Journal

Potency evaluation of erythropoietin products: current status ; Оценка специфической активности препаратов эритропоэтина: современное состояние

Authors: L. A. Gaiderova, N. A. Alpatova, S. L. Lysikova, A. M. Guskov, O. V. Golovinskaya, Л. А. Гайдерова, Н. А. Алпатова, С. Л. Лысикова, А. М. Гуськов, О. В. Головинская

Contributors: This study was conducted by the Scientific Centre for Expert Evaluation of Medicinal Products as part of the applied research funded under State Assignment No. 056-00026-24-01 (R&D Registry No. 124022200103-5), Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00026-24-01 на проведение прикладных научных исследований (номер государственного учета НИР 124022200103-5)

Source: Biological Products. Prevention, Diagnosis, Treatment; Том 24, № 4 (2024); 443-455 ; БИОпрепараты. Профилактика, диагностика, лечение; Том 24, № 4 (2024); 443-455 ; 2619-1156 ; 2221-996X ; 10.30895/2221-996X-2024-24-4

File Description: application/pdf

Relation: https://www.biopreparations.ru/jour/article/view/614/945; https://www.biopreparations.ru/jour/article/downloadSuppFile/614/1072; https://www.biopreparations.ru/jour/article/downloadSuppFile/614/1130; Халимова АА, Орлов АС, Таубэ АА. Анализ локализации производства биотехнологических лекарственных препаратов в России с учетом происхождения активных фармацевтических субстанций. Биотехнологичекие лекарственные препараты. Ведомости научного центра экспертизы средств медицинского применения. Регуляторные исследования и экспертиза лекарственных средств. 2024;14(1):54–61. https://doi.org/10.30895/1991-2919-2024-14-1-53-61; Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2):205–8. https://doi.org/10.1084/jem.20122760; Толкушин АГ, Холовня-Волоскова МЭ, Завьялов АА, Лучинин ЕА. Обзор потребления лекарственных препаратов в рамках льготного лекарственного обеспечения пациентов с некоторыми злокачественными новообразованиям лимфатической и кроветворной тканей на территории г. Москвы в 2019 г. Современная организация лекарственного обеспечения. 2021;8(3):22–31. https://doi.org/10.30809/solo.3.2021.3; Волкова РА, Фадейкина ОВ, Устинникова ОБ, Саркисян КА, Мовсесянц АА. Меркулов ВА, Косенко ВВ. Требования к материалам раздела по стандартным образцам, представляемым в досье на биологические лекарственные средства. БИОпрепараты. Профилактика, диагностика, лечение. 2024;24(1):7–20. https://doi.org/10.30895/2221-996X-2024-24-1-7-20; Ramos AS, Schmidt CA, Andrade SS, Fronza M, Rafferty B, Dalmora SL. Biological evaluation of recombinant human erythropoietin in pharmaceutical products. Braz J Med Biol Res. 2003;36(11):1561–9. https://doi.org/10.1590/s0100-879x2003001100014; Cowper B, Hockley J, Partridge K, Ferguson J, Rigsby P, Burns Ch. The first World Health Organization International Standard for in vitro biological activity of darbepoetin. Biologicals. 2020;(63):33–8. https://doi.org/10.1016/j.biologicals.2019.12.004; Меркулов ВА, Солдатов АА, Авдеева ЖИ, Алпатова НА, Гайдерова ЛА, Яковлев АК, Медуницын НВ. Препараты рекомбинантных эритропоэтинов и их характеристика. БИОпрепараты. Профилактика, диагностика, лечение. 2013;(3):4–11. EDN: RDXVGT; Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012;318(9):1068–73. https://doi.org/10.1016/j.yexcr.2012.02.035; Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol. 2004;32(12):1146–55. https://doi.org/10.1016/j.exphem.2004.08.004; Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem. 1987;262(25):12059–76. PMID: 3624248; Molineux G, Sinclair AM. Biology of erythropoietin. In: Elliott SG, Foote MA, Molineux G, eds. Erythropoietins, erythropoietic factors, and erythropoiesis. Milestones in drug therapy. Basel: Birkhäuser; 2009. P. 41–60. https://doi.org/10.1007/978-3-7643-8698-6_3; Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40(5):302–9. https://doi.org/10.1159/000356193; Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med. 2013;3(3):a011619. https://doi.org/10.1101/cshperspect.a011619; Moradi Z, Maali A, Shad JS, Farasat A, Kouchaki R, Moghadami M, et al. Updates on novel erythropoiesis-stimulating agents: clinical and molecular approach. Indian J Hematol Blood Transfus. 2020;36(1):26–36. https://doi.org/10.1007/s12288-019-01170-1; Варламова ОН, Червяковская ОД. Эритропоэтин и его биологическая роль. Медицина. Теория и практика. 2019;4(3):61–69. EDN: NWDVPG; Иваненко КА, Прасолов ВС, Хабушева ЭР. Транскрипционный фактор Sp1 в регуляции экспрессии генов, кодирующих компоненты сигнальных путей MAPK, JAK/STAT и PI3K/Akt. Молекулярная биология. 2022;56(5):832–47. https://doi.org/10.31857/S0026898422050081 https://doi.org/10.1134/s0026893322050089; Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79. https://doi.org/10.1038/s41419-020-2276-8; Meager A. Measurement of cytokines by bioassays: theory and application. Methods. 2006;8(4):237–52. https://doi.org/10.1016/j.ymeth.2005.11.005; Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;(1):1–10. https://doi.org/10.1186/2110-5820-1-3; Takeuchi M, Takasaki S, Shimada M, Kobata A. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. J Biol Chem. 1990;265(21):12127–30. https://doi.org/10.1016/S0021-9258(19)38318-8; Dong YJ, Kung C, Goldwasser E. Receptor binding of asialoerythropoietin. J Cell Biochem. 1992;48(3):269–76. https://doi.org/10.1002/jcb.240480307; Imai N, Higuchi M, Kawamura A, Tomonoh K, Oh-Eda M, Fujiwara M, et al. Physicochemical and biological characterization of asialoerythropoietin: suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem. 1990;194(2):457–62. https://doi.org/10.1111/j.1432-1033.1990.tb15639.x; Zimmermann H, Gerhard D, Hothorn LA, Dingermann T. An alternative to animal testing in the quality control of erythropoietin. Pharmeur Bio Sci Notes. 2011;2011(1):66–80. PMID: 21619857; Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood. 1995;86(11):4097–104. https://doi.org/10.1182/blood.V86.11.4097.bloodjournal86114097; Hua S, Oh MJ, Ozcan S, Seo YS, Grimm R, An HJ. Technologies for glycomic characterization of biopharmaceutical erythropoietins. Trends Anal Chem. 2015;68:18–27. https://doi.org/10.1016/j.trac.2015.02.004; Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood. 2001;98(13):3626–34. https://doi.org/10.1182/blood.v98.13.3626; Zhang P, Woen S, Wang T, Liau B, Zhao S, Chen C, et al. Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discovery Today. 2016;21(5):740–65. https://doi.org/10.1016/j.drudis.2016.01.006; Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler Th, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther. 2018;18(4):369–79. https://doi.org/10.1080/14712598.2018.1421169; Susantad T, Fuangthong M, Tharakaraman K, Tit-Oon P, Ruchirawat M, Sasisekharan R. Modified recombinant human erythropoietin with potentially reduced immunogenicity. Sci Rep. 2021;11(1):1491. https://doi.org/10.1038/s41598-020-80402-1; Петренко АА, Пивник АВ, Дудина ГА, Дубницкая МГ. Парциальная красноклеточная аплазия костного мозга в сочетании с тимомой. Обзор литературы и собственные данные. Терапевтический архив. 2019;91(7):121–6. https://doi:10.26442/00403660.2019.07.000326; Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000;20(4):375–81. PMID: 10928340; Macdougall IC, Robson R, Opatrna S, Lioqier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1(6):1211–5. https://doi.org/10.2215/cjn.00730306; Barth T, Oliveira PR, D’Avila FB, Dalmora SL. Validation of the normocythemic mice bioassay for the potency evaluation of recombinant human erythropoietin in pharmaceutical formulations. J AOAC Int. 2008;91(2):285–91. https://doi.org/10.1093/jaoac/91.2.285; Яковлев АК, Гайдерова ЛА, Подкуйко ВН, Волкова РА, Алпатова НА, Олефир ЮВ. Изучение возможности гармонизации метода определения специфической активности рекомбинантных эритропоэтинов с требованиями Европейской фармакопеи. Эталоны. Стандартные образцы. 2016;(3):4–11. EDN: XHDFRJ; Metta MK, Malkhed V, Tantravahi S, Vuruputuri U, Kunaparaju R. Development of an in vitro bioassay for recombinant human erythropoietin (rHuEPO) based on proliferative stimulation of an erythroid cell line and analysis of sialic acid dependent microheterogeneity: UT-7 cell bioassay. Protein J. 2017;36(2):112–22. https://doi.org/10.1007/s10930-017-9704-3; Obora S, Kurosawa T. Implementation of the three Rs in biomedical research — has the turn of the century turned the tide? Altern Lab Anim. 2009;37(2):197–207. https://doi.org/10.1177/026119290903700209; Lang C, Kolaj-Robin O, Cirefice G, Taconet L, Pel E, Jouette S, et al. Replacement, reduction, refinement-animal welfare progress in European Pharmacopoeia monographs: activities of the European Pharmacopoeia Commission from 2007 to 2017. Pharmeur Bio Sci Notes. 2018;2018:12–36. PMID: 29845933; Machado FT, Maldaner FP, Perobelli RF, Xavier B, da Silva FS, de Freitas GW, et al. Evaluation of an in vitro cell culture assay for the potency assessment of recombinant human erythropoietin. Altern Lab Anim. 2016;44(2):113–20. https://doi.org/10.1177/026119291604400207; Yang Y, Zhou Y, Yu L, Li X, Shi X, Qin X, et al. A novel reporter gene assay for recombinant human erythropoietin (rHuEPO) pharmaceutical products. J Pharm Biomed Anal. 2014;100: 316–21. https://doi.org/10.1016/j.jpba.2014.08.003; Liefooghe EC, Tiplady R, Gerson P, Lloyd P, Heath A, Bristow AF. A sialylation-sensitive cell-based in vitro bioassay for erythropoietin; incorporation of the galactose-binding Erythrina crista-galli lectin. Biologicals. 2005;33(3):161–7. https://doi.org/10.1016/j.biologicals.2005.05.001; Jeong TH, Son YJ, Ryu HB, Koo BK, Jeong SM, Hoang P, et al. Soluble expression and partial purification of recombinant human erythropoietin from E. coli. Protein Expr Purif. 2014;95:211–8. https://doi.org/10.1016/j.pep.2014.01.001; Гаврилова НА, Черепушкин СА, Рыкалина НВ, Обухов ЮИ. Разработка метода определения биологической активности препаратов эритропоэтина in vitro. БИОпрепараты. Профилактика, диагностика, лечение. 2016;16(2):120–4. EDN: WAIVXP; Wang L, Yu Ch, Junzhi Wang J. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnol Adv. 2020;39:107466. https://doi.org/10.1016/j.biotechadv.2019.107466; Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, et al. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res. 2010;8(4):615–26. https://doi.org/10.1158/1541-7786.MCR-09-0264; Ma R, Hu J, Huang C, Wang M, Xiang J, Li G. JAK2/ STAT5/Bcl-xL signalling is essential for erythropoietin-mediated protection against apoptosis induced in PC 12 cells by the amyloid β−peptide Aβ25–35. Br J Pharmacol. 2014;171(13):3234–45. https://doi.org/10.1111/bph.12672; Tu H, Carrick K, Potts R, Hasselberg M, Verdecia M, Burns C, et al. A reference standard for analytical testing of erythropoietin. Pharm Res. 2022;39(3):553–62. https://doi.org/10.1007/s11095-022-03213-1; Camiscoli JF, Weintraub AH, Gordon AS. Comparative assay of erythropoietin standards. Ann N Y Acad Sci. 1968;149(1):40–5. https://doi.org/10.1111/j.1749-6632.1968.tb15133.x; Cotes PM, Bangham DR. The international reference preparation of erythropoietin. Bull World Health Organ. 1966;35(5):751–60. PMID: 5297809; Annable L, Cotes PM, Mussett MV. The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull World Health Organ. 1972;47(1):99–112. PMID: 4538911; Storring PL, Gaines Das RE. The international standard for recombinant DNA-derived erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol. 1992;134(3):459–84. https://doi.org/10.1677/joe.0.1340459; Behr-Gross ME, Daas A, Bristow AF. Collaborative study for the establishment of erythropoietin BRP batch 2. Pharmeuropa Bio. 2004;(1):23–33. PMID: 15659283; Яковлев АК, Гайдерова ЛА, Алпатова НА, Лобанова ТН, Постнова ЕЛ, Юрчикова ЕИ и др. Изучение принципов стандартизации фармакологической активности препаратов рекомбинантных эритропоэтинов. Эталоны. Стандартные образцы. 2016;(1):8–20. EDN: VXVOJB; Behr-Gross ME, Daas A, Burns C, Bristow AF. Collaborative study for the establishment of erythropoietin BRP batch 3. Pharmeuropa Bio. 2007;(1):49–66. PMID: 18413137; Burns C, Bristow AF, Buchheit KH, Daas A, Wierer M, Costanzo A. Establishment of the Ph. Eur. erythropoietin chemical reference substance batch 1. Pharmeur Bio Sci Notes. 2015;2015:99–117. PMID: 26830161; Burns C, Bristow AF, Daas A, Costanzo A. Collaborative study for the establishment of erythropoietin BRP batch 4. Pharmeur Bio Sci Notes. 2015;2015:246–53. PMID: 26830170; Ferguson J, Burns CJ, Regourd E, Costanzo A. Collaborative study for the establishment of erythropoietin BRP batch 5. Pharmeur Bio Sci Notes. 2019;2019:27–33. PMID: 30880683; Cowper B, Hockley J, Partridge K, Ferguson J, Rigsby P, Burns C. The first World Health Organization International Standard for in vitro biological activity of darbepoetin. Biologicals. 2020;63:33–8. https://doi.org/10.1016/j.biologicals.2019.12.004; Jelkmann W. Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant. 2009;24(5):1366–8. https://doi.org/10.1093/ndt/gfp058; https://www.biopreparations.ru/jour/article/view/614